Old Drugs, New Prices: How Pharma Justifies Premium Pricing for Repurposed Medicines
The hook:
Repurposed medicines aren’t new—yet their price tags often are. And the justification is getting more sophisticated.
In the last decade, “drug repurposing” h…

Pharma hiring isn’t just about résumés—it’s about citations.
If you’re recruiting in life sciences, you already know the usual playbook: pedigree schools, impressive job titles, and a list of publications that look good in a PDF. But in a world where…

Old Drugs. New Prices. Same Molecule. The Pharma Playbook Is Getting Sharper.
There’s a quiet shift happening across healthcare: repurposed medicines—often decades old—are being reintroduced with premium pricing, backed by a familiar narrative of “inno…

Pharma has a new playbook—and it’s not always about new science.
In a world where “innovation” is the currency of premium pricing, drugmakers increasingly justify higher costs for repurposed medicines using a familiar narrative: same molecule, new valu…

Russia’s “third wheel” rule is more than bureaucracy—it’s a signal.
In the world of pharmaceuticals, the loudest moves often happen quietly: in patent filings, in regulatory language, and in the fine print of “who is allowed to do what” inside a supp…

Europe’s divisional patent game: how “final decisions” get delayed—and why it matters for generics
The most consequential patent battles in Europe don’t always end in court. Sometimes, they end in time.
In a recent analysis by DrugPatentWatch, Europe’s…

Pharma patent litigation used to be a $50M inevitability.
Now, it’s increasingly a $5M decision.
That’s not a slogan—it’s the direction of travel described in a recent DrugPatentWatch piece on how companies are cutting the cost of patent enforcement an…

PBMs and rebates aren’t “background noise” anymore—they’re the business model.
If you’re a pharma executive, payer strategy isn’t a side project. It’s the battlefield. And the rules of engagement are changing faster than most organizations can update t…

Mark Cuban’s Cost-Plus Pricing Isn’t Just a Pricing Story—It’s a Patent-Playbook Story
The most important thing to understand about Mark Cuban’s cost-plus pricing push isn’t that it’s “cheaper.” It’s that it’s changing the incentives that have governed…

{
“error”: {
“message”: “You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.”,
“type”: “insufficient_quota”,
“pa…